DarzalexActive Ingredient(s): Daratumumab
FDA Approved: * November 16, 2015
Pharm Company: * JANSSEN BIOTECH
Daratumumab, sold under the brand name Darzalex, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab. Daratumumab was granted breakthrough ... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.
Darzalex 100 mg/5ml Intravenous Injection, Solution, ConcentrateNDC: 57894-502
Janssen Biotech, Inc.